Literature DB >> 8846496

Modern treatment of haemophilia.

E Berntorp1, V Boulyjenkov, D Brettler, M Chandy, P Jones, C Lee, J Lusher, P Mannucci, I Peak, K Rickard.   

Abstract

Many rapid advances have been made in the diagnosis and therapy of haemophilia. Nevertheless, the condition still poses problems and challenges (e.g., joint disease, transfusion-transmitted diseases, inhibitors, provision of care in developing countries, and education and cost issues). WHO and the World Federation of Hemophilia held a joint meeting in Geneva, on 21-23 March 1994, to discuss and review current and future approaches to the management of haemophilia and its complications, including prospects for genetic technology and gene therapy in developed and developing countries. The present review article summarizes the discussions and recommendations made by the participants.

Entities:  

Mesh:

Year:  1995        PMID: 8846496      PMCID: PMC2486807     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  18 in total

1.  Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.

Authors:  I M Nilsson; E Berntorp
Journal:  Prog Clin Biol Res       Date:  1990

2.  Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

Authors:  I M Nilsson; E Berntorp; T Löfqvist; H Pettersson
Journal:  J Intern Med       Date:  1992-07       Impact factor: 8.989

3.  Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII.

Authors:  Y Sultan; G C White; A Aronstam; C Bosser; H H Brackmann; G Brochier; J Gormsen; G Mariani; H R Roberts; Y Scarabin
Journal:  Nouv Rev Fr Hematol       Date:  1986

4.  Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates.

Authors:  H G Watson; C A Ludlam; S Rebus; L Q Zhang; J F Peutherer; P Simmonds
Journal:  Br J Haematol       Date:  1992-04       Impact factor: 6.998

5.  Acute hepatitis A in patients with haemophilia A.

Authors:  K Peerlinck; J Vermylen
Journal:  Lancet       Date:  1993-01-16       Impact factor: 79.321

6.  Transmission of human parvovirus B19 by coagulation factor concentrates.

Authors:  M D Williams; B J Cohen; A C Beddall; K J Pasi; P P Mortimer; F G Hill
Journal:  Vox Sang       Date:  1990       Impact factor: 2.144

7.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.

Authors:  S Ehrenforth; W Kreuz; I Scharrer; R Linde; M Funk; T Güngör; B Krackhardt; B Kornhuber
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

8.  The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.

Authors:  D B Brettler; A D Forsberg; P H Levine; L M Aledort; M W Hilgartner; C K Kasper; J M Lusher; C McMillan; H Roberts
Journal:  Arch Intern Med       Date:  1989-06

9.  Adjusted dose continuous infusion of factor VIII in patients with haemophilia A.

Authors:  U Martinowitz; S Schulman; S Gitel; H Horozowski; M Heim; D Varon
Journal:  Br J Haematol       Date:  1992-12       Impact factor: 6.998

10.  A multicenter study of viral hepatitis in a United States hemophilic population.

Authors:  C L Troisi; F B Hollinger; W K Hoots; C Contant; J Gill; M Ragni; R Parmley; C Sexauer; E Gomperts; G Buchanan
Journal:  Blood       Date:  1993-01-15       Impact factor: 22.113

View more
  39 in total

1.  [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].

Authors:  Jin-Mu Zhuang; Xue-Yan Sun; Xuan Zhou; Zhu-Qin Liu; Jing Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

2.  Need for Prophylactic Treatment in Adult Haemophilia A Patients.

Authors:  Berthold Siegmund; Heinrich Richter; Hartmut Pollmann
Journal:  Transfus Med Hemother       Date:  2009-07-10       Impact factor: 3.747

Review 3.  Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.

Authors:  Elena Santagostino; Maria Elisa Mancuso
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

Review 4.  Secondary prophylaxis in adolescent and adult haemophiliacs.

Authors:  Annarita Tagliaferri; Caterina Di Perna; Gianna Franca Rivolta
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

Review 5.  Practical aspects of extended half-life products for the treatment of haemophilia.

Authors:  Thierry Lambert; Gary Benson; Gerry Dolan; Cedric Hermans; Victor Jiménez-Yuste; Rolf Ljung; Massimo Morfini; Silva Zupančić-Šalek; Elena Santagostino
Journal:  Ther Adv Hematol       Date:  2018-09-06

6.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

7.  Target of prophylaxis in severe haemophilia: more than factor levels.

Authors:  Antonio Coppola; Massimo Franchini
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

8.  The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia.

Authors:  Sweta Gupta; Azfar-E-Alam Siddiqi; J Michael Soucie; Marilyn Manco-Johnson; Roshni Kulkarni; Heidi Lane; Robina Ingram-Rich; Joan C Gill
Journal:  Br J Haematol       Date:  2013-02-22       Impact factor: 6.998

Review 9.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

10.  Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.

Authors:  Steven Pipe
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.